IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

Clinical trial NCT01885897 · COMPLETED

Trial details

NCT number: NCT01885897
Sponsor: Masonic Cancer Center, University of Minnesota
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myelogenous Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)Myelodysplastic Syndromes (MDS)Lymphoma Myeloma Chronic Lymphocytic Leukemia (CLL)Chronic Myelogenous Leukemia (CML)

Start date: 2013-11-11
Primary completion: 2019-07-01
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.